Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
12,274 total articles
Swarmer, a NASDAQ-listed drone autonomy software company, shared a letter from Chairman Erik Prince discussing the company's strategic shift toward becoming a platform that acquires and partners with battlefield-proven defense technology firms. With its software proven in over 100,000 combat missions in Ukraine, Swarmer aims to capitalize on growin…
Immuneering Corporation has dosed the first patient in the global pivotal Phase 3 MAPKeeper 301 trial, evaluating the efficacy and safety of atebimetinib plus modified gemcitabine/nab-paclitaxel (mGnP) compared to standard GnP alone in first-line metastatic pancreatic cancer patients. The trial aims to improve overall survival and quality of life f…
Medicus Pharma Ltd. (NASDAQ: MDCX) announced submission of an Investigational New Drug (IND) application to initiate PRECISION-E2, a first-of-its-kind Phase 2a clinical trial integrating genomics to evaluate Teverelix® for symptomatic endometriosis in women in the UAE. The study combines clinical, hormonal, pharmacokinetic, and genomic data from pa…
Helus Pharma, a clinical-stage pharmaceutical company specializing in novel serotonergic agonists (NSAs) for mental health conditions, announced that its Chief Medical Officer, Amir Inamdar, will participate in a fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Conference. The company highlighted its lead drug candidates HLP003 in…
Rafael Holdings reported its Q3 fiscal 2026 financial results, highlighting the completion of the last patient last visit in its pivotal Phase 3 trial for Trappsol® Cyclo™, a treatment for Niemann-Pick Disease Type C1 (NPC). The company plans to submit a New Drug Application (NDA) in the second half of 2026, aiming to enter the commercial stage. Fi…
Cronos Group announces that its Spinach® vape portfolio has become the leading vape brand in Canada, holding a 10.4% market share as of April 2026. The company attributes this success to high product quality, innovative formulations, and advanced hardware. Cronos plans to launch new flavors and products this summer, aiming at further expanding its …
Quantum Cyber announces the creation of an Advanced Filament Manufacturing Division at its Connecticut facility to produce proprietary EMP-hardened composite filaments for its 3D printer drone production farm and external defense customers. This vertical integration aims to reduce costs, protect proprietary technology, and position the company to c…
Syndax Pharmaceuticals reported robust clinical activity of its FDA-approved menin inhibitor, Revuforj (revumenib), presented at EHA 2026. Data from real-world studies, phase 1 and 2 trials indicate high response rates and durable remissions in relapsed/refractory and newly diagnosed patients with NPM1-mutated, KMT2A-rearranged, and NUP98-rearrange…
Kyivstar Group Ltd., a Nasdaq-listed Ukrainian digital operator, announced that its ride-hailing service Uklon has launched "Uklon Store," an in-app marketplace initially offering flower delivery in Kyiv. This marks Uklon's first expansion beyond mobility services into everyday commerce, leveraging Uklon's 5.1 million active users and delivery netw…
Medifast Inc. emphasizes the unique metabolic challenges women face during perimenopause and menopause, promoting its OPTAVIA weight management program designed specifically to reduce visceral fat while preserving lean muscle. The company backs its approach with clinical research highlighting significant fat loss and muscle retention when compared …
Medifast, trading under NYSE: MED, emphasizes the scientific rigor behind its OPTAVIA weight loss program, which is backed by randomized controlled trials using clinical gold-standard DXA scanning to track body composition changes. The company highlights strong weight loss outcomes, high study completion rates, and significant fat loss with lean ma…
Kyivstar Group Ltd., a Nasdaq-listed Ukrainian digital operator, announced that its subsidiary Uklon has launched Uklon Store, an in-app marketplace starting with a Flowers category in Kyiv. This strategic move aims to accelerate ecosystem monetization by leveraging Uklon's ride-hailing infrastructure to enter e-commerce, increase user engagement, …
Relmada Therapeutics appointed Michael Quirk, PhD, a CNS drug development expert, as Senior Advisor for its sepranolone program targeting Prader-Willi Syndrome and other CNS disorders. Dr. Quirk's extensive experience in neuroactive steroid biology and translational neuroscience is expected to advance clinical development of sepranolone, a GABAA re…
The Lovesac Company reported its first quarter fiscal 2027 results with net sales largely flat compared to the prior year, driven by showroom expansion offset by shop-in-shop closures. Gross profit and margin contracted due to higher transportation and tariff costs, despite price increases and cost initiatives. The company continues to advance new …
C4 Therapeutics presented Phase 1 trial results for cemsidomide, an oral IKZF1/3 degrader, showing a 53% overall response rate at the recommended Phase 2 dose in heavily pretreated relapsed/refractory multiple myeloma patients. The treatment was well tolerated with manageable side effects, supporting further development as a foundational therapy ac…
Tilray Brands' BrewDog is marking Scotland's national football team return with a limited-time promotion that rolls pint prices back to £2 at Scottish BrewDog bars for a 72-hour weekend and launches a £19.98 online beer bundle. This campaign aims to increase footfall, celebrate local heritage, and expand e-commerce sales, supporting BrewDog's broad…
Tonix Pharmaceuticals Holding Corp., a US-listed biotechnology company specializing in CNS and immunology treatments, announced its executive team's participation in BTIG Infectious Disease Day 2026, held virtually on June 16, 2026. The company focuses on commercial-stage products for fibromyalgia and migraines, while advancing a pipeline addressin…
Aqua Metals, Inc. has been selected as the industrial partner in a DOE-funded program led by Idaho National Laboratory to develop electrochemical methods for refining nickel and cobalt from lithium-ion battery recycling streams. This collaboration leverages Aqua Metals' pilot facilities and expertise to enhance domestic critical minerals refining t…
Climb Bio announced initial Phase 1b clinical data demonstrating that Budoprutug, an anti-CD19 monoclonal antibody, exhibits an encouraging safety profile, robust B-cell depletion, and meaningful platelet response in heavily pretreated adult patients with primary immune thrombocytopenia (ITP). The data were presented at the European Hematology Asso…
Purple Biotech Ltd. presented new preclinical data at EACR 2026 showcasing its lead immunotherapy candidate IM1240, part of the CAPTN-3 platform. The data indicate significant improvements in pharmacokinetics, safety, and anti-tumor efficacy, particularly in immunotherapy-resistant cancers such as head and neck, bladder, and non-small cell lung can…
Nurix Therapeutics announced updated Phase 1a/b clinical trial results for bexobrutideg (NX-5948), an oral BTK degrader, demonstrating high objective response rates and durable progression-free survival in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients, including those with prior BTK inhibitor resista…
Syndax Pharmaceuticals announced the publication and presentation of Phase 1/2 SAVE trial data evaluating an all-oral combination of Revuforj (revumenib), decitabine/cedazuridine, and venetoclax in patients with relapsed or refractory acute myeloid leukemia (AML) characterized by NPM1 mutation, KMT2A rearrangement, or NUP98 rearrangement. The trial…
AC Immune SA, a clinical-stage biopharmaceutical company listed on NASDAQ (ticker: ACIU), announced it will receive a $4 million research grant from The Vijay and Marie Goradia Charitable Foundation. The grant will fund an extension of Part 1 of the ongoing Phase 2 VacSYn trial of ACI-7104, an active immunotherapy targeting alpha-synuclein in early…
Pharvaris announced its Annual General Meeting of shareholders scheduled for June 26, 2026. The company is advancing its late-stage biopharmaceutical pipeline focused on oral bradykinin B2 receptor antagonists targeting hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH). Pharvaris is preparing marketing a…
Kimco Realty OP, LLC priced $525 million of 3.50% exchangeable senior notes due 2031, increased from $500 million, with proceeds to partially repurchase common stock and for general corporate purposes including debt repayment and acquisitions. Notes are exchangeable into Kimco common stock at a premium and carry optional redemption features. The of…
